Report Highlights
The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
Report Includes
- 25 data tables and 66 additional tables
- Analyses of the trends in the global market for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
- Facts and figures pertaining to the market dynamics, technological advances, regulatory landscape, and the impact of macroeconomic factors
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Bristol-Myers Squibb, Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific and Qiagen
Report Scope
This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.
In this report, BCC Research estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.
This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $4.4 Billion | ||||||||||||||||
| Market size forecast | $8.5 Billion | ||||||||||||||||
| Growth rate | CAGR of 11.8% from 2024 to 2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | By Product Type, Study Method, Clinical Indication, Drug Class and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and the Rest of the World (RoW) | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global epigenomic market reached nearly $4 billion in 2014 and $4.7 billion in 2015. The market should reach nearly $12.1 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 20.6% from 2015 to 2020.
Report Highlights
- The global market for personalized medicine technology is projected to be $14.4 billion in 2009 and is expected to reach $29.2 billion in 2014, for a compound annual growth rate (CAGR) of 15.2%
- Pharmacogenomics is a major revenue generating market, contributing about 28.7% to the total personalized medicine market in 2009, at $4.1 billion; this should reach $9.5 billion in 2014, for a CAGR of 18%
- The point-of-care market has the second largest share of the market, at $2.7 billion in 2009. This is expected to increase to $5.1 billion in 2014, for a CAGR of 18%.
Report Highlights
-
The worldwide market for pharmacogenomics reached $1.24 billion in 2004 and is projected to rise at an average annual growth rate (AAGR) of 24.5% to reach $3.7 billion by 2009.
-
Diagnostics comprised 39.2% of the total market in 2004 and are projected to rise at an AAGR of 28.4% to account for 45.3% of the total in 2009.
-
Genotyping technologies are expected to expand at an AAGR of 26.5% to reach $1.7 billion or 44% of the total market.
-
SNP identification technologies reached sales of $200.7 million in 2004 and are projected to increase at an AAGR of 14.6% to reach $397.2 million in 2009.
Related Reports
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Single-Cell Genomics and Proteomics: Emerging Technologies and Markets
The global market for single-cell genomics and proteomics is expected to grow from $4.0 billion in 2024 to reach $9.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 17.6% from 2024 through 2029.
2024 Medical Devices Research Review
The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Recent Reports
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Nanotechnology in Cancer Treatment: Technologies and Global Markets
The report provides an analysis of the global market for nanotechnology in cancer treatment. Using 2023 as the base year, the report provides estimated market data for 2024 through 2029. The market in this report is segmented into product type, cancer type, and region. The report concludes with profiles of the major players in the market.
Radiopharmaceuticals: Technologies and Global Markets
The global radiopharmaceuticals market is expected to grow from $10.3 billion in 2024 and is projected to reach $21.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 16.4% during the forecast period of 2024 to 2029.
Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
Epigenetics: Technologies and Global Markets
The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
Top Trending Reports
Global Diabetic Care Devices Market
The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.
Carbon Capture, Utilization & Storage Technologies
The global market for carbon capture, utilization and storage (CCUS) technologies is expected to grow from $3.4 billion in 2024 and is projected to reach $9.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.1% during the forecast period of 2024 to 2029.
2024 Semiconductor Manufacturing Research Review
This 2024 Research Review of the Semiconductor Manufacturing provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions.
2024 Medical Devices Research Review
The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.
Generative AI: Global Markets
The global market for generative AI was valued at $15.4 billion in 2023. It is projected to grow from $20.8 billion in 2024 to $94.4 billion by 2029, at a compound annual growth rate (CAGR) of 35.3% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More